Compare Intuit Inc. (INTU) vs Pfizer Inc (PFE) Price & Performance

Intuit (INTU) trades at $336.44, up 3.44% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $18.83B in 2025, with a net income margin of 20.54%, while analyst consensus is a Buy with a $401 price target. However, recent news highlights a 20% stock drop and securities fraud investigations related to TurboTax pricing issues, creating near-term uncertainty.

The outlook is mixed: strong fundamentals and AI-driven growth in financial software support upside, but legal risks and investor sentiment pressure pose challenges. Valuation metrics like a P/E of 20.4 appear reasonable if execution continues, yet volatility may persist until legal concerns resolve.

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.